Drug intelligence / Profile preview

TEV-316

Development stage: Preclinical
Lead developer: Teva Pharmaceutical Industries
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

TEV-316 is a biosimilar monoclonal antibody developed by Teva Pharmaceutical Industries. It is in preclinical development as of May 2025, with its primary investigated indication listed generally as neoplasms. Precise target or mechanism of action is not specified in public sources. There is no evidence of FDA or EMA approval, and detailed clinical or pharmacological information remains unavailable based on current records.

Beyond the preview

Go deeper on TEV-316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-316.

Explore the full profile